Thank you, Mr. Chair.
Ms. Silas, as we speak today, the pharmacare act is receiving its third vote in the Senate. Once it receives its majority vote, it is slated to get royal assent today. My understanding is that the Conservative leader in the Senate is delaying that, so that the royal assent that was scheduled for later tonight now has to be postponed.
I'm just wondering if you could explain to us what you see as the health benefits and maybe the economic impacts of having two classes of drug—diabetes medications and devices, and contraception medications and devices.
What impact might it have on Canadians' health and economic situations to have access to those drugs through their public health care system at no cost to them?